Premium
Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent
Author(s) -
Harousseau J. L.,
RigalHuguet F.,
Hurteloup P.,
Guy H.,
Milpied N.,
Pris J.
Publication year - 1989
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1989.tb01208.x
Subject(s) - idarubicin , myeloid leukemia , medicine , myeloid , oncology , leukemia , cytarabine
Idarubicin (IDR) is a new anthracycline that can be administered orally. Oral IDR was given at a dose of 30 mg/m 2 daily for 3 d in 20 patients aged 65 to 79 yr with previously untreated acute myeloid leukemia (AML). 5 patients whose marrow remained blastic at d 14 received a second course. 8 patients achieved complete remission (6 after one single course). There were: 1 early death, 4 deaths in aplasia, 7 failures. The hematologic toxicity was high. All but 1 patient had to stay in hospital and the duration of neutropenia was 12 to 34 d (median 19). Oral IDR is an effective therapy for AML in elderly patients but the total dose of 90 mg/m 2 is too aggressive to be administered safely outside the hospital.